December 19, 2006 12:40 PM Eastern Time
Understand How Nanotechnology is Revolutionizing Drug Delivery
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c47332)
has announced the addition of Innovation in Drug Delivery: The Future of
Nanotechnology and Non-invasive Protein Delivery to their offering.
Drug delivery is one of the most dynamic and fast growing sectors of the
pharmaceutical industry. The high level of innovation in this sector is
evolving at a fast pace with products such as Pfizer’s
inhaled insulin, Exubera, gaining US approval in January 2006.
‘Innovation in Drug Delivery’
provides an in-depth examination of product launches and pipeline drugs
with novel drug delivery mechanisms set to revolutionize the market,
such as products using ALZA Corporation’s
E-TRANS and Altea’s PassPort patch transdermal
technologies. This report will enable you to evaluate key marketed
drugs, including Emend and Megace, and gain an insight into novel
pipeline products to anticipate upcoming product launches and position
yourself for success.
Use this report to understand how nanotechnology and other key
technologies are changing drug delivery and how these can be implemented
into your R&D process. Assess the impact of innovation in therapy areas
including oncology, diabetes and infectious diseases and identify future
opportunities for market growth.
Some key findings from this report:
Solubility is a key resistor to drug delivery and a major factor
causing attrition and poor efficacy in drug development, with an
estimated 30% of drugs in pre-clinical development having low
Abraxane and Doxil are both innovative marketed oncology products
utilizing nanotechnology, gaining sales of $184m and $177m in the US
and 5 major European countries in 2005, respectively.
There are several high potential inhaled monoclonal antibodies in
development, including products from Enzon and Nektar, Alexion and
Medimmune, and Alkermes.
Active transdermal patches are predominantly indicated for pain and
women’s health, but products using ALZA’s
E-TRANS and Altea’s PassPort patch
technology are predicted to available for protein delivery within the
next few years, and consequently will increase the range of accessible
indications for transdermal delivery.
Drug eluting stents are typically 3 to 4 fold more expensive than bare
metal stents and have elicited safety concerns, however next
generation drug-eluting stents consist of bio-absorbable polymers and
are predicted to be safer.
Key questions answered in this report:
What are the key drivers of innovation in drug delivery and how are
they impacting the pharmaceutical market?
How is nanotechnology driving forward innovation and what is its
impact on each therapy area?
What strategies are the leading drug delivery companies implementing
to maximize sales and boost market share?
Who are the leading innovators in transdermal and pulmonary drug
Which new product launches will gain high sales and challenge the
current market leaders?
What are the key trends in drug delivery and how will they impact
Which innovative drug delivery technologies have the highest future
Top five reasons to order your copy today:
Understand how nanotechnology is revolutionizing drug delivery and how
this can be implemented into your own R&D process.
Evaluate key marketed drugs with innovative drug delivery and gain
insight into novel pipeline products to identify your competitive
position and anticipate upcoming product launches.
Gain access to the latest information on key technologies in drug
delivery, with the report’s comprehensive
coverage of leaders in each field.
Assess the impact of innovation in drug delivery in therapy areas
including oncology, diabetes and infectious diseases and identify
future opportunities for market growth.
Implement strategies to address the key unmet needs in drug delivery
and current and future challenges in key indications, enabling you to
plan for future success.
Chapter 1 Introduction
Chapter 2 Advances in nanotechnology
Chapter 3 Targeted therapies in oncology
Chapter 4 Innovation in pulmonary delivery
Chapter 5 Innovation in transdermal delivery
Chapter 6 Innovation in medical devices
Chapter 7 Competitive landscape
Chapter 8 The future of drug delivery
List of Figures
List of Tables
- Altea Therapeutics
- ALZA Corporation
- Abraxis BioScience
- Michigan Nanotechnology Institute for Medicine and Biological
- TransPharma Medical
- Flamel Technologies
- ZARS Pharma
For more information visit http://www.researchandmarkets.com/reports/c47332
Source: Business Insights